The digital translational neuroimaging group focuses on the preclinical and clinical evaluation of new radiopharmaceuticals for nuclear medicine diagnostics of patients with brain tumours (e.g., gliomas and metastases) using positron emission tomography (PET) and the correlation and investigation of advanced magnetic resonance imaging (MRI) techniques. This includes the assessment of amino acid uptake in brain tumours, along with modern developments in functional MRI, including structural and functional connectivity and the clinical application of correlative hybrid PET/MRI for diagnosis, therapy planning and therapy response assessment in brain tumour patients.
Further, to enhance the potential of PET/MRI for brain tumour diagnostics, quantitative image analysis methods, including artificial intelligence technologies such as radiomics and deep learning, are being developed and evaluated.
Additional fields of specialist interest include the evaluation of the therapeutic effects of novel amyloid-β binding peptide ligands for neurodegenerative diseases such as Alzheimer’s using behavioural tests, autoradiography, as well as PET and MRI.
RECENT PUBLICATIONS